

EMA/181816/2017

European Medicines Agency decision

P/0087/2017

of 24 March 2017

on the acceptance of a modification of an agreed paediatric investigation plan for talimogene laherparepvec (Imlygic), (EMA-001251-PIP01-11-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0087/2017

of 24 March 2017

on the acceptance of a modification of an agreed paediatric investigation plan for talimogene laherparepvec (Imlygic), (EMA-001251-PIP01-11-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0047/2013 issued on 1 March 2013, the decision P/0105/2016 issued on 15 April 2016 and the decision P/0353/2016 issued on 9 December 2016,

Having regard to the application submitted by Amgen Europe B.V. on 12 December 2016 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and proposing a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 24 February 2017, in accordance with Article 22 of Regulation (EC) No 1901/2006, and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.
- (3) It is therefore appropriate to adopt a decision on the granting of a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for talimogene laherparepvec (Imlygic), solution for injection, intralesional use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

A waiver for talimogene laherparepvec (Imlygic), solution for injection, intralesional use, the details of which are set out in the opinion of the Paediatric Committee the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Amgen Europe B.V., Minervum 7061, 4817-ZK - Breda, The Netherlands.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/857548/2016
London, 24 February 2017

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001251-PIP01-11-M03

Scope of the application

Active substance(s):

Talimogene laherparepvec

Invented name:

Imlygic

Condition(s):

Treatment of solid malignant non-CNS tumours

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Intralesional use

Name / corporate name of the PIP applicant:

Amgen Europe B.V.

Information about the authorised medicinal product:

See Annex II



Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Amgen Europe B.V. submitted to the European Medicines Agency on 12 December 2016 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0047/2013 issued on 1 March 2013, the decision P/0105/2016 issued on 15 April 2016 and the decision P/0353/2016 issued on 9 December 2016.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral and proposed a waiver.

The procedure started on 3 January 2017.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified. A waiver for a new paediatric subset has been added.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion;
 - to grant a waiver for one or more subsets of the paediatric population concluded in accordance with Article 11(1)(c) of Regulation (EC) No 1901/2006 as amended, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of solid malignant non-CNS tumours

The waiver applies to:

- the paediatric population from birth to less than 2 years;
- solution for injection, intralesional use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition

Treatment of solid malignant non-CNS tumours

2.1.1. Indication(s) targeted by the PIP

Treatment of paediatric patients with a solid malignant non-CNS tumour as part of a multi-modal treatment approach

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection for intralesional use

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	2	Study 1 Paediatric tumour cell cytotoxicity study. Study 2 Paediatric tumour model xenograft study.
Clinical studies	2	Study 3 Multi-centre, open-label, dose de-escalation study to evaluate the tolerability, safety and activity of talimogene laherparepvec in patients from 2 years of age with melanoma or with an advanced non-CNS tumours that are amenable to direct injection and for which no effective treatment is known.

		Study 4 Randomised, controlled trial to evaluate the safety and efficacy of talimogene laherparepvec in patients from 2 years of age with a malignant solid non-CNS tumour as part of a multi-modal treatment approach.
--	--	--

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By January 2027
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of melanoma

Authorised indication(s):

- Imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.

Authorised pharmaceutical form(s):

Solution for injection

Authorised route(s) of administration:

Intralesional use